US Capitol Capsule: Will Myriad BRCA case relieve biopharma's patent anxiety?
This article was originally published in Scrip
Executive Summary
Dumbfounded by the US Supreme Court's 20 March decision invalidating diagnostic methods patents held by Prometheus Laboratories, the biopharma industry is bracing for the next court battle about what is or isn't patentable subject matter when the US Court of Appeals for the Federal Circuit hears oral arguments on 20 July on whether Myriad Genetics' composition patent claims covering the BRCA1 and BRCA2 genes are valid.